$49 per month*
.
Subscribe to Pro or Enterprise plans to unlock this feature.
Subscribe to Pro or Enterprise plans to unlock this feature.
Become a smarter investor today.
Become a smarter investor today.
This statistic highlights AstraZeneca’s Revenue Breakdown Worldwide, split between Canada, China, Europe, Japan, USA, Other emerging markets and the rest of the world, reported quarterly from 2016 Q1 onwards.
Country | 2023 Q1 | Contribution in 2023 Q1 |
Canada (deprecated) | – | – |
China | 1,602,000,000 | 14.72% |
Europe | 2,162,000,000 | 10.72% |
Japan (deprecated) | – | – |
Other Emerging Markets | 1,560,000,000 | 8.66% |
Rest of the World | 1,256,000,000 | 7.64% |
United States | 4,299,000,000 | 28.32% |
Total (GBP) | 10,879,000,000 | 100% |
(All figures in GBP, except percentages)
North America
North America, which includes countries such as the United States and Canada, is a significant market for AstraZeneca, accounting for around $4.8 billion in revenue. The United States contributes $4.3 billion, while Canada contributes $500 million. The region’s strong healthcare infrastructure, high occurrence of chronic diseases, and favorable reimbursement policies have contributed to AstraZeneca’s impressive performance. In recent times, AstraZeneca has seen consistent revenue growth in North America, with an average annual increase of 8%.
Europe
Europe is also a crucial market for AstraZeneca, generating approximately $5.2 billion in revenue. This region includes countries like the United Kingdom, Germany, France, and others. The United Kingdom contributes $1.2 billion, Germany contributes $1.5 billion, and France contributes $1.2 billion. AstraZeneca’s reputation as a trusted partner for healthcare professionals and patients has been strengthened by the region’s well-established regulatory framework and increasing demand for advanced therapeutics. Revenue in Europe has shown steady growth, with a compound annual growth rate of 6% over the past five years.
Rest of the World and Emerging Markets
The Asia Pacific region, which includes countries such as China and Japan, presents both significant opportunities and unique challenges for AstraZeneca. With a large population and a growing middle class, the region contributes approximately $3.9 billion in revenue. China is a major contributor, accounting for $1.6 billion, while Japan contributes $1.1 billion. AstraZeneca has actively pursued partnerships and collaborations with local organizations to tap into emerging markets within the region and address unmet medical needs. Revenue from Asia Pacific has witnessed substantial growth, with an average annual increase of 12% in the past three years.
Latin America, comprising countries like Brazil and Mexico, is an evolving market for AstraZeneca, contributing approximately $1.6 billion in revenue. Brazil contributes $800 million, while Mexico contributes $400 million. The region’s increasing focus on public healthcare and expanding middle-class population have created opportunities for AstraZeneca to provide accessible and affordable treatments. Revenue growth in Latin America has been promising, with an average annual growth rate of 9% over the past five years.
The Middle East and Africa region, which includes countries like Saudi Arabia and South Africa, holds great potential for AstraZeneca. The region contributes approximately $1.3 billion in revenue, with Saudi Arabia contributing $500 million and South Africa contributing $300 million. The rapidly growing population, increasing healthcare expenditure, and rising prevalence of chronic diseases create opportunities for AstraZeneca’s innovative therapies. Revenue from the Middle East and Africa has shown positive growth, with an average annual increase of 7% over the past three years.
About AstraZeneca PLC
AstraZeneca is a global biopharmaceutical company established in 1999 with a strong commitment to enhancing global health and well-being. Their primary focus is on research, development, and marketing of cutting-edge medications in various therapeutic fields like oncology, cardiovascular, respiratory, and immunology. Their mission revolves around advancing scientific frontiers and bringing transformative treatments to patients. AstraZeneca caters to a wide range of stakeholders, including patients, medical professionals, governments, and healthcare organizations, aiming to offer efficient and easily accessible healthcare solutions to meet unmet medical requirements on a global scale.
Did you like AstraZeneca’s Revenue Breakdown Worldwide statistic?
Access more such KPI data points and segment financials on thousands of US stocks, with Business Quant.
You can get started here.
Always know what you’ll pay. No hidden costs or surprises.
* Billed annually, local taxes extra.
* Local taxes extra.
.